Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A research-based pharmaceutical company focused on neurology and oncology treatments.

4523 | T

Overview

Corporate Details

ISIN(s):
JP3160400002
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号

Description

Eisai Co., Ltd. is a research-based global pharmaceutical company engaged in the discovery, development, manufacture, and marketing of prescription medicines. The company's primary business activities are concentrated in the therapeutic areas of neurology, with a significant focus on dementia-related diseases, and oncology. Guided by its core "human health care" (hhc) philosophy, Eisai prioritizes the needs of patients and their families. The company is dedicated to developing innovative and targeted treatments for challenging medical conditions and actively promotes initiatives to improve access to medicines in developing and emerging countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-08-09 03:08
確認書
Japanese 8.0 KB
2023-08-09 03:06
四半期報告書-第112期第1四半期(2023/04/01-2023/06/30)
Japanese 257.2 KB
2023-06-21 07:53
内部統制報告書-第111期(2022/04/01-2023/03/31)
Japanese 21.3 KB
2023-06-21 07:51
確認書
Japanese 8.1 KB
2023-06-21 07:49
有価証券報告書-第111期(2022/04/01-2023/03/31)
Japanese 3.4 MB
2023-02-14 02:11
確認書
Japanese 8.1 KB
2023-02-14 02:09
四半期報告書-第111期第3四半期(2022/10/01-2022/12/31)
Japanese 324.3 KB
2022-11-09 02:14
確認書
Japanese 8.2 KB
2022-11-09 02:13
四半期報告書-第111期第2四半期(令和4年7月1日-令和4年9月30日)
Japanese 344.5 KB
2022-08-05 07:07
確認書
Japanese 8.1 KB
2022-08-05 07:05
四半期報告書-第111期第1四半期(令和4年4月1日-令和4年6月30日)
Japanese 268.2 KB
2022-06-17 08:06
確認書
Japanese 8.1 KB
2022-06-17 08:05
内部統制報告書-第110期(令和3年4月1日-令和4年3月31日)
Japanese 21.4 KB
2022-06-17 08:02
有価証券報告書-第110期(令和3年4月1日-令和4年3月31日)
Japanese 2.5 MB
2022-02-14 02:09
四半期報告書-第110期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 306.0 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Eisai Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.